|
|
Article: Aricept and Aciphex boost Eisai results.(pharmaceutical industry)
- Article from:
- Pharma Marketletter
- Article date:
- June 6, 2005
CopyrightCOPYRIGHT 2005 Marketletter Publications Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Japan's Eisai reported solid consolidated results for the fiscal year to March 2005 on growth of its two global compounds, the Alzheimer's disease drug Aricept (donepezil) and the antiulcerant Aciphex/Pariet (rabeprazole). Total revenues increased 6.6% year-on-year to 533.0 billion yen ($4.96 billion), exceeding the target of 530.0 billion yen. Operating profit was up 4.5% to 86.8 billion yen and recurring income rose 6.8% to 89.1 billion yen. Net income increased 10.7% to 55.5 billion yen, slightly above the target of 54.0 billion yen. Net income growth was assisted by a decline in the effective tax rate of 3.6 percentage points to 36.3%.
Global revenues from ...
Related newspaper, magazine, and journal articles:
|
|
Article: Japan's Daiichi Sankyo aims for sales of 960B yen in 2009, ...
Pharma Marketletter;
February 26, 2007 ;
700+ words
... ... 10% to 470.0 billion yen in 2009 with a sales force ... strengthen sales in the USA by 2009. Daiichi Sankyo ... of about 100.0 billion yen in 2006 to 200.0 billion ... Another subsidiary in the USA, Luitpold Inc, aims to ... revenues of 60.0 billion yen or more by maintaining ...
|
|